Advances in targeted therapy for triple-negative breast cancer: a review of key antigens and recent advances., PMID:40515614
The antibody-drug conjugate sacituzumab govitecan (IMMU-132) represents a potential novel therapeutic strategy in cholangiocarcinoma., PMID:40509933
A Meta-Analysis of Patient-Reported Outcomes of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Previously Treated HR+/HER- mBC Using Two Phase 3 (TROPiCS-02 and EVER-132-002) Trials., PMID:40507364
Advancing Antibody-Drug Conjugates: Precision Oncology Approaches for Breast and Pancreatic Cancers., PMID:40507272
Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data., PMID:40507234
Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: Two recently developed chemotherapies in the crucial battle against breast cancer., PMID:40502326
Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy., PMID:40494034
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies., PMID:40481574
Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States., PMID:40479864
Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma., PMID:40479863
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study., PMID:40460679
Mechanisms of resistance to antibody-drug conjugates in cancers., PMID:40460510
New Treatment Approaches for Triple-Negative Breast Cancer., PMID:40460322
Evaluation of sacituzumab govitecan for advanced/metastatic non-small cell lung cancer., PMID:40458070
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis., PMID:40456670
Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan., PMID:40440568
Last Resort? Rationale for Comprehensive Molecular Analysis in Treatment-Refractory R/M HNSCC: A Case Report of Remarkable Response to Sacituzumab Govitecan Following Molecular and Functional Characterization., PMID:40427091
ADCs and TCE in SCLC Therapy: The Beginning of a New Era?, PMID:40422520
Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer., PMID:40397834
A Multicenter Real-Life Evaluation of Safety and Effectiveness of the Antibody-Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer., PMID:40387297
Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast Cancer., PMID:40386501
Progress of antibody-drug conjugates in the treatment of locally advanced or metastatic urothelial carcinoma: opportunities and challenges., PMID:40377724
Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer., PMID:40371894
[Translated article] Influence of the UGT1A1 gene polymorphism on treatment with sacituzumab govitecan. Narrative review., PMID:40368667
Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing., PMID:40367401
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan., PMID:40366333
The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey., PMID:40361516
TROP2 expression and therapeutic targeting in uterine carcinosarcoma., PMID:40344963
Navigating antibody‒drug conjugates (ADCs): from metastatic to early breast cancer treatment strategies., PMID:40304863
MMP1-induced NF-κB activation promotes epithelial-mesenchymal transition and sacituzumab govitecan resistance in hormone receptor-positive breast cancer., PMID:40287412
[Diffuse interstitial lung disease induced by antibody-drug conjugates]., PMID:40263022
Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review., PMID:40260055
Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer., PMID:40252843
Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution., PMID:40238068
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)., PMID:40234477
Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing., PMID:40201309
Trop2-expression in primary vulvar squamous cell carcinoma., PMID:40184712
Safety and Tolerability of Concurrent Radiotherapy and Sacituzumab Govitecan in Metastatic Breast Cancer., PMID:40178882
Advances in adoptive cell therapies in small cell lung cancer., PMID:40160238
Toxicities and management strategies of emerging antibody-drug conjugates in breast cancer., PMID:40151551
Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index., PMID:40149365
Influence of the UGT1A1 gene polymorphism on treatment with sacituzumab govitecan. Narrative review., PMID:40140308
Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer., PMID:40136373
Correction to: Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial., PMID:40132065
Toxicities Associated with Sacituzumab Govitecan: Data from Clinical Trials and a Real-World Pharmacovigilance Database., PMID:40131630
Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review., PMID:40124876
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines., PMID:40118736
Antibody-drug conjugates in breast cancer: current evidence and future directions., PMID:40114224
Antibody-drug conjugates in rare genitourinary tumors: review and perspectives., PMID:40110990
Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in China., PMID:40108623
For research use only. Not for human or drug use.
